In short, GLP-1s work with the bodys own systems to improve blood sugar control and, for some people, support weight management
Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-analysis and meta-regression
Consequently the FDA issued a drug-specific black box warning for rosiglitazone concerning an increased risk of ischemic cardiovascular events (separate from the warning for increased risk of heart failure, which remains in effect)
Among these patients, 45.2% achieved a dose of 1 mg (injectable), and 14.2% reached 14 mg (oral) [1]
The study looked at weight loss results in 14,000 non-diabetic patients
Kate Wolin Resources: [2] [3] [4] [5] [6] Longevity by Design is a podcast for individuals looking to experience longer, healthier lives